A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

• Status: Recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bioverativ - a sanofi company; Bioverativ, a Sanofi company
• Treatments: Busulfan; JM 3100; Plerixafor

Criteria

Inclusion Criteria

• Ages 18 to 40

• Confirmation of sickle cell disease (SCD) diagnosis (HbSS or HbS[beta]0 genotype)

• Severe SCD, defined as having 1 or more of the following manifestations: Clinically significant neurologic event (example [e.g.], stroke) or any neurological deficit lasting more than 24 hours; History of 2 or more episodes or Acute Chest Syndrome (ACS) in 2 years prior to informed consent (despite adequate supportive therapies such as asthma therapy); Six or more pain crises per year in 2 years prior to informed consent (requiring intravenous [IV] pain management in the outpatient or inpatient hospital setting); History of 2 or more cases or priapism with participant seeking medical care in the 2-years prior to informed consent; Regular RBC transfusion therapy in the year prior to informed consent (having received 8 or more transfusions to prevent vaso-occlusive clinical complications); and Echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity of greater than or equal to 2.5 meter per second (m/s)

• Clinically stable to undergo stem cell mobilization and myeloablative hematopoietic stem cell transplantation (HSCT)

• Adequate physiological function, defined as the following: Karnofsky/Lansky Performance of greater than or equal to 60; Acceptable cardiac function as defined in protocol; Acceptable pulmonary function as defined in protocol; Acceptable renal function as defined in protocol; and Acceptable hepatic function as defined in protocol

• Ability to understand purpose and risks of study, provide Informed Consent Form (ICF) and authorization to use protected health information

• Completion of age-appropriate cancer screening

• Willingness to use double-barrier method of contraception through entire study period (for participants of childbearing potential)

• Willingness to receive blood transfusions

• Willingness to discontinue hydroxyurea (HU) at least 30 days prior to stem cell mobilization through Day 100 post-transplantation

Exclusion Criteria:

• Previous receipt of an autologous or allogeneic HSCT or solid organ transplantation

• Previous treatment with gene therapy

• Current enrollment in an interventional study or having received an investigational drug within 30 days of study enrollment

• Pregnant or breastfeeding female

• Female or male who plans to become pregnant or impregnate a partner, respectively, during the anticipated study period

• Contraindication to plerixafor, apheresis, or busulfan

• Treatment with prohibited medication in previous 30 days

• Known allergy or hypersensitivity to plerixafor, busulfan, or investigational product excipients

• History of active malignancy within past 5 years, any history of hematologic malignancy, or a family history of a cancer predisposition syndrome (without negative result of candidate)

• Current diagnosis of uncontrolled seizures

• History of significant bleeding disorder

• Clinically significant infection

• Any major organ dysfunction involving brain, kidney, liver, lung, or heart (e.g., congestive heart failure, pulmonary hypertension)

• Corrected QT interval of more than 500 millisecond (ms) based on screening electrocardiogram (ECG)

• Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)

• Known to have a gamma-globin variant associated with altered oxygen affinity

• Hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration of more than or equal to 20 percent (%) at screening

• Absolute Neutrophil Count (ANC) of less than or equal to 1,000 per microliter

• Platelet count of less than 100,000 per microliter

• History of platelet alloimmunization (precluding ability to provide transfusion support)

• Extensive Red Blood Cell (RBC) alloimmunization (precluding ability to provide transfusion support)

• Judged unsuitable for participation by investigator and/or sponsor